Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma?

Cancer

Volumn 121, Issue 22, 2015, Pages 3998-4006

  Spolverato, Gaya ^a   Vitale, Alessandro ^b   Cucchetti, Alessandro ^c   Popescu, Irinel ^d   Marques, Hugo P ^e   Aldrighetti, Luca ^f   Gamblin, T Clark ^g   Maithel, Shishir K ^h   Sandroussi, Charbel ⁱ   Bauer, Todd W ^j   Shen, Feng ^k   Poultsides, George A ^l   Marsh, J Wallis ^m   Pawlik, Timothy M ^a,n  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d FUNDENI CLINICAL INSTITUTE   (Romania)

^e HOSPITAL CURRY CABRAL   (Portugal)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g MEDICAL COLLEGE OF WISCONSIN   (United States)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j UNIVERSITY OF VIRGINIA   (United States)

^k Eastern Hepatobiliary Surgery Hospital   (China)

^l STANFORD UNIVERSITY   (United States)

^m UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

ⁿ JOHNS HOPKINS HOSPITAL   (United States)

more..

Author keywords

cure; hepatic resection; intrahepatic cholangiocarcinoma; surgery

Indexed keywords

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LIVER RESECTION; LONG TERM CARE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; STATISTICAL MODEL; TUMOR INVASION; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; MIDDLE AGED; MORTALITY; PATHOLOGY;

AGED; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; FEMALE; HEPATECTOMY; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED;

EID: 84946491620     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29619     Document Type: Article

References (35)

1. El-Serag HB, Engels EA, Landgren O, et al., Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans. Hepatology. 2009; 49: 116-123.
2. Endo I, Gonen M, Yopp AC, et al., Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008; 248: 84-96.
3. Malhi H, Gores GJ,. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol. 2006; 45: 856-867.
4. Shaib YH, Davila JA, McGlynn K, El-Serag HB,. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004; 40: 472-477.
5. Bosman FT,; World Health Organization; International Agency for Research on Cancer. World Health Organization Classification of Tumours of the Digestive System. 4th ed. Lyon, France: International Agency for Research on Cancer; 2010.
6. de Jong MC, Nathan H, Sotiropoulos GC, et al., Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011; 29: 3140-3145.
7. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
8. Greene FL, Page DL, Flemming ID, et al., AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
9. Nathan H, Aloia TA, Vauthey JN, et al., A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2009; 16: 14-22.
10. Okabayashi T, Yamamoto J, Kosuge T, et al., A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables. Cancer. 2001; 92: 2374-2383.
11. Yamasaki S,. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg. 2003; 10: 288-291.
12. Nathan H, Pawlik TM,. Staging of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol. 2010; 26: 269-273.
13. Nathan H, Pawlik TM, Wolfgang CL, Choti MA, Cameron JL, Schulick RD,. Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg. 2007; 11: 1488-1496; discussion 1496-1487.
14. Maetani S, Gamel JW,. Evolution of cancer survival analysis. Surg Oncol. 2010; 19: 49-51; discussion 61.
15. Lambert PC, Thompson JR, Weston CL, Dickman PW,. Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics. 2007; 8: 576-594.
16. Othus M, Barlogie B, Leblanc ML, Crowley JJ,. Cure models as a useful statistical tool for analyzing survival. Clin Cancer Res. 2012; 18: 3731-3736.
17. Cai C, Zou Y, Peng Y, Zhang J,. smcure: an R-package for estimating semiparametric mixture cure models. Comput Methods Programs Biomed. 2012; 108: 1255-1260.
18. Cvancarova M, Aagnes B, Fossa SD, Lambert PC, Moller B, Bray F,. Proportion cured models applied to 23 cancer sites in Norway. Int J Cancer. 2013; 132: 1700-1710.
19. Dal Maso L, Guzzinati S, Buzzoni C, et al,; AIRTUM Working group. Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types. Ann Oncol. 2014; 25: 2251-2260.
20. Couinaud C,. Liver anatomy: portal (and suprahepatic) or biliary segmentation. Dig Surg. 1999; 16: 459-467.
21. Smoll NR, Schaller K, Gautschi OP,. The cure fraction of glioblastoma multiforme. Neuroepidemiology. 2012; 39: 63-69.
22. Cucchetti A, Ferrero A, Cescon M, et al., Cure model survival analysis after hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2015; 22: 1908-1914.
23. Tsodikov AD, Ibrahim JG, Yakovlev AY,. Estimating cure rates from survival data: an alternative to two-component mixture models. J Am Stat Assoc. 2003; 98: 1063-1078.
24. National Center for Health Statistics. Title. Available at: http://ftp.cdc.gov/pub/health-statistics/NCHS/Publications/NVSR/62-07/. Accessed on October 6th, 2014.
25. Patel T,. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001; 33: 1353-1357.
26. Shaib Y, El-Serag HB,. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004; 24: 115-125.
27. Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM,. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis [published online ahead of print April 9, 2014 ]. JAMA Surg. doi: 10.1001/jamasurg.2013.5137.
28. Spolverato G, Ejaz A, Kim Y, et al., Tumor size predicts vascular invasion and histologic grade among patients undergoing resection of intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2014; 18: 1284-1291.
29. Hyder O, Marques H, Pulitano C, et al., A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience. JAMA Surg. 2014; 149: 432-438.
30. Wang Y, Li J, Xia Y, et al., Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013; 31: 1188-1195.
31. Boag JW,. Maximum likelihood estimates of the proportion of patients cured by cancer therapy. J R Stat Soc [B]. 1949; 11: 15-53.
32. Berkson J, Gage R,. Survival curve for cancer patients following treatment. J Am Stat Assoc. 1952; 47: 501-515.
33. De Angelis R, Capocaccia R, Hakulinen T, Soderman B, Verdecchia A,. Mixture models for cancer survival analysis: application to population-based data with covariates. Stat Med. 1999; 18: 441-454.
34. Spolverato G, Kim Y, Alexandrescu S, et al., Is hepatic resection for large or multifocal intrahepatic cholangiocarcinoma justified? Results from a multi-institutional collaboration. Ann Surg Oncol. 2015; 22: 2218-2225.
35. Hyder O, Hatzaras I, Sotiropoulos GC, et al., Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery. 2013; 153: 811-818.